CYTLIMIC
CYTLIMIC is a biotechnology company developing immunotherapy products for the treatment of cancer, including a cancer peptide vaccine. CYTLIMIC’s products aim to activate immune systems to attack cancer cells while enabling patients to maintain a high quality-of-life during treatment.
CYTLIMIC
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2016-12-16
Address:
Higashi-shinagawa, Tokyo, Japan
Country:
Japan
Website Url:
http://www.cytlimic.com
Total Employee:
1+
Status:
Active
Total Funding:
20.85 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Nginx
Current Advisors List
Current Employees Featured
Founder
Investors List
SMBC Venture Capital
SMBC Venture Capital investment in Series B - Cytlimic
Fast Track Initiative, Inc.
Fast Track Initiative, Inc. investment in Series B - Cytlimic
NEC Capital Solutions
NEC Capital Solutions investment in Series B - Cytlimic
Fast Track Initiative, Inc.
Fast Track Initiative, Inc. investment in Seed Round - Cytlimic
Fast Track Initiative, Inc.
Fast Track Initiative, Inc. investment in Series A - Cytlimic
NEC Capital Solutions
NEC Capital Solutions investment in Series A - Cytlimic
SMBC Venture Capital
SMBC Venture Capital investment in Series A - Cytlimic